Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DLBS 3233

Drug Profile

DLBS 3233

Alternative Names: DLBS-3233; Inlacin

Latest Information Update: 04 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dexa Medica
  • Class Antihyperglycaemics; Thiazolidinediones
  • Mechanism of Action Adiponectin stimulants; GLUT4 stimulants; Lipoprotein modulators; Peroxisome proliferator-activated receptor gamma modulators; Phosphatidylinositol 3 kinase alpha modulators; Proto oncogene protein c akt modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Polycystic ovary syndrome

Most Recent Events

  • 31 May 2019 Dexa Medica Group completes the phase III POSITIF trial in Polycystic ovary syndrome in Indonesia (PO) (NCT01999686)
  • 01 Apr 2018 Dexa Medica completes a phase III trial for Polycystic ovary syndrome in Indonesia (NCT01733459)
  • 11 Jun 2015 No recent reports of development identified - Phase-III for Type-2 diabetes mellitus (Prevention) in Indonesia (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top